Tempus AI Stock Jumps, ALERT Trial Results Boost EHR Automation Buzz

Tempus AI Inc. (NASDAQ: TEM) shares rose 3.54% to $46.82 following positive results from the ALERT trial, which showed a 40% increase in life-saving valve procedures and a 27% rise in heart team evaluations due to an automated electronic health record (EHR) notification system. The trial involved 765 clinicians and highlighted the potential of AI-driven alerts to improve care delivery. Additionally, Tempus has expanded its collaboration with Merck & Co. to enhance precision medicine efforts, with analysts maintaining a Buy rating and an average price target of $72.00.